Home›Crovalimab›Crovalimab + Eculizumab

Does Crovalimab Interact with Eculizumab?

Crovalimab and Eculizumab have a major drug interaction according to U.S. FDA drug labeling data. Formation of dual targeting drug complexes (DTDCs) when switching between crovalimab and eculizumab can result in Type III hypersensitivity reactions. DTDCs expected to clear within approximately 8 weeks. The mechanism involves crovalimab and eculizumab bind different epitopes on c5, forming dtdcs that may trigger type iii hypersensitivity reactions. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Crovalimab Class
Complement C5 Inhibitor
Eculizumab Class
Complement Inhibitor
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Crovalimab and Eculizumab occurs because crovalimab and eculizumab bind different epitopes on c5, forming dtdcs that may trigger type iii hypersensitivity reactions. Clinically, this means formation of dual targeting drug complexes (dtdcs) when switching between crovalimab and eculizumab can result in type iii hypersensitivity reactions. dtdcs expected to clear within approximately 8 weeks. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Crovalimab and your doctor is considering prescribing Eculizumab (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Crovalimab(Piasky)+💊 Eculizumab

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Complement C5 Inhibitor
Drug B class
Complement Inhibitor
Source
NLP:crovalimab

What this means in plain English

Formation of dual targeting drug complexes (DTDCs) when switching between crovalimab and eculizumab can result in Type III hypersensitivity reactions. DTDCs expected to clear within approximately 8 weeks.

What the FDA label says

"Crovalimab and eculizumab bind different epitopes on C5, forming DTDCs that may trigger Type III hypersensitivity reactions"

📖 Source: NLP:crovalimab

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Crovalimab and Eculizumab against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.